Case Report
Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide (1). Epidermal growth factor receptor (EGFR) mutations, as driver oncogenes, were first identified in NSCLC in 2004 (2).
